Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset
- PMID: 3119213
- PMCID: PMC11038001
- DOI: 10.1007/BF00199148
Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset
Abstract
In the present study we investigated some of the physicochemical properties of macrophage-activating factor(s) (MAF) produced by the tumor-immune Lyt-1+2- T cell subset. Supernatant from mixed culture of spleen and lymph node cells, obtained from C3H/HeN mice immunized with syngeneic MH134 hepatoma or MCH-1-A1 fibrosarcoma, with the corresponding tumor cells exhibited the capability of activating peritoneal exudate macrophages to exert their cytostatic and cytolytic activities on tumor cells. Such MAF production was abolished by treatment of tumor-immune spleen and lymph node cells with anti-Thy-1.2 or anti-Lyt-1.1 antibody plus complement (C) before culturing. Anti-Lyt-2.1 and/or anti-asialo GM1 plus C treatment, however, had only marginal effect on the generation of MAF by these cells, despite the complete disappearance of natural killer (NK) cell activity of spleen and lymph node cells after the treatment with anti-asialo GM1 plus C. Thus, the tumor-specific Lyt-1+2- T cell subset could fulfill a crucial role in generating MAF without the support of NK cells. The MAF activity was heat, acid, and trypsin sensitive. On Sephacryl S-300 column, MAF activity was eluated in a broad single peak around a molecular weight (m.w.) of 70,000 daltons. Antiviral activity was detected in the concentrated pool of MAF-containing fractions from Sephacryl S-300. Gel permeation analysis using HPLC also showed a coincident peak of MAF and antiviral activities at a m.w. of approximately 70,000 daltons. In addition, MAF activity was almost completely neutralized by incubation with rabbit antiserum against recombinant murine gamma-interferon (IFN gamma). Taken together, these results indicate that MAF generated by tumor-immune Lyt-1+2- T cell subset is closely related to IFN gamma.
Similar articles
-
Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.J Immunol. 1985 Sep;135(3):2199-205. J Immunol. 1985. PMID: 3894520
-
Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.Jpn J Cancer Res. 1986 Nov;77(11):1142-52. Jpn J Cancer Res. 1986. PMID: 3098724
-
The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. II. Lyt-1+2- T cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells.Cancer Immunol Immunother. 1987;24(1):8-12. doi: 10.1007/BF00199826. Cancer Immunol Immunother. 1987. PMID: 3493074 Free PMC article.
-
The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.J Immunol. 1985 Sep;135(3):2187-91. J Immunol. 1985. PMID: 3874911
-
Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF).Immunobiology. 1989 Jun;179(2-3):131-44. doi: 10.1016/s0171-2985(89)80012-9. Immunobiology. 1989. PMID: 2676851
Cited by
-
Salivary macrophage chemokines as potential biomarkers of gingivitis.BMC Oral Health. 2023 Feb 6;23(1):77. doi: 10.1186/s12903-023-02787-5. BMC Oral Health. 2023. PMID: 36747174 Free PMC article.
-
The mode of recognition of tumor antigens by noncytolytic-type antitumor T cells: role of antigen-presenting cells and their surface class I and class II H-2 molecules.Cancer Immunol Immunother. 1988;27(3):261-6. doi: 10.1007/BF00205449. Cancer Immunol Immunother. 1988. PMID: 3141057 Free PMC article.
-
Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.Cancer Metastasis Rev. 1988 Dec;7(4):289-309. doi: 10.1007/BF00051371. Cancer Metastasis Rev. 1988. PMID: 2974763 Review.
References
-
- Cohen S. Lymphokines in delayed hypersensitivity. In: Fougereau M, Dausset J, editors. Progress in immunology, 4. New York: Academic Press; 1980. p. 860.
-
- Conta BS, Powell MB, Ruddle NH. Production of lymphotoxin, IFN-γ and IFN-α,β by murine T cell lines and clones. J Immunol. 1983;130:2231. - PubMed
-
- Erickson KL, Cicurel L, Gruys E, Fidler IJ. Murine T cell hybridomas that produce lymphokine with macrophage-activating factor activity as a constitutive product. Cell Immunol. 1982;72:195. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources